---
topic: Eczema-Diverticular Disease Connection
tags: [eczema, psoriasis, atopic-dermatitis, diverticular-disease, skin-gut-axis, gut-microbiome, inflammation, IBD, calprotectin, barrier-dysfunction]
priority: important
last_updated: 2026-05-04
confidence: medium-high
abstract: >-
  Skin-gut biology is plausible through barrier, microbiome, allergic, and immune pathways,
  but the actionable conclusion is modest. The useful microbiome actions are boring and
  log-driven: tolerated fiber/plant diversity, optional fermented foods, one probiotic at a
  time if symptoms or eczema justify it, and bile-acid/SIBO branches only by pattern. Broad
  commercial microbiome sequencing, fecal SCFA panels, TMAO chasing, and histamine narratives
  are not core next steps.
open_questions:
  - How much of the remaining inflammatory tone is skin/allergic rather than gut-driven now that calprotectin normalized?
  - Would dermatology review change treatment enough to reduce systemic inflammatory noise?
---

# Eczema-Diverticular Disease Connection

## Summary

The practical model is evidence-tiered, not “eczema causes diverticular disease.”

Dag’s history does support a skin-gut hypothesis: chronic eczema/psoriasis-overlap, dry eyes/meibomian blockage, IgE elevation, gut symptoms, alcohol sensitivity, and eczema improvement during diet/probiotic periods. But April 2026 also limits the claim: calprotectin is now normal, while occult blood and platelet/WBC issues persist. That means skin/allergic activity may contribute to systemic inflammatory tone, but it should not be used to explain stool blood or diverticular bleeding.

## Evidence tiers

| Tier | What is supported | What is not supported |
|---|---|---|
| Established | Atopic dermatitis and psoriasis associate with immune dysregulation, barrier dysfunction, microbiome changes, and higher IBD/autoimmune comorbidity risk. | That eczema directly causes diverticular bleeding. |
| Plausible | Skin and gut symptoms can move together through microbiome, SCFA, alcohol/barrier effects, mast-cell/allergic tone, and Th2/Th17 immune overlap. | That improving eczema means the colon is structurally safer. |
| Weak / speculative | Psoriasis may have a small observational association with diverticulitis; gut-directed interventions may help some eczema symptoms. | That the association is large enough to drive GI strategy by itself. |
| Not supported | Eczema as the explanation for positive FOB/stool RBCs, ferritin drift, or a diverticular hemorrhage event. | Using eczema control as a bleeding-risk biomarker. |

## Microbiome actionability — useful vs noisy

Classification: **INTEGRATE**. The gut-heart-skin microbiome queue item resolves here as a practical filter across the existing SIBO, probiotic, skin-gut, inflammatory, and supplement pages. The current evidence supports low-risk pattern work, not broad microbiome diagnostics.

| Claim / lever | Evidence tier | What to do now | What not to buy or infer |
|---|---|---|---|
| Fiber, plant diversity, resistant starch / inulin-type fermentable fibers | Strongest practical lever; human reviews support modest inflammatory benefits and SCFA-related mechanisms, but exact fiber type/dose remains individualized | Keep tolerated plant-forward/high-fiber pattern; titrate slowly during bloating phases; use logs, stool quality, circumference, iron timing, and symptom response | Do not chase fecal SCFA panels or assume one “butyrate score” changes management |
| Fermented foods / yogurt / kefir | Plausible food-level support; evidence is product- and person-specific | Optional small daily fermented food if tolerated and not worsening histamine-like symptoms, bloating, or stool looseness | Do not treat “fermented” as automatically anti-inflammatory or safer for diverticular bleeding |
| Probiotics | Mixed, strain-specific evidence; SUDD data show possible pain benefit with low/very-low certainty, adult AD meta-analyses suggest modest severity improvement | Use one base probiotic only if logs show gut or skin benefit; stop/rotate only as structured trials; CBM588 remains a targeted option if exact strain is sourced | Do not stack multiple probiotics indefinitely or use them as stool-blood/bleeding prevention |
| Broad commercial stool microbiome sequencing | 2025 international consensus: clinical usefulness remains scarce/limited and DTC testing risks waste and mismanagement | Skip unless a specialist uses a validated test for a specific decision | Do not buy broad “gut health” reports to pick supplements, diagnose dysbiosis, explain Lp(a), or reassure stool blood |
| TMAO / heart microbiome biomarkers | TMAO associates with CV outcomes, but clinical utility for this profile is not established and diet confounding is substantial | Keep outcome-proven CV levers first: smoking abstinence, BP, ApoB/LDL, imaging, exercise, diet quality | Do not test TMAO or use it to override Lp(a)/ApoB/BP/imaging decisions |
| Histamine / mast-cell narratives | Histamine intolerance has no validated biomarker; diagnosis is symptom-response and reintroduction based | Consider only if reproducible flushing/itch/headache/diarrhea pattern follows high-histamine foods | Do not make broad low-histamine restriction a default during an already complex gut experiment |
| Bile acids / SIBO / MMC | Plausible subphenotypes for post-meal bloating/urgency/loose stool; needs pattern matching | Keep symptom branch separate: meal spacing, stool form, urgency, fat-meal response, circumference, breath-test/GI review only if it would change treatment | Do not use microbiome language to explain positive FOB/stool RBC or ferritin/TSAT drift |
| Eczema / IgA / systemic inflammation | Skin-gut/allergic immune overlap is plausible; adult AD probiotic data are modest; IgA/ESR can add context | Treat skin disease directly and use diet/probiotic effects only as logged symptom signals | Do not infer hidden gut bleeding or platelet cause from eczema improvement/worsening |

## Current signal

Relevant personal signals:

- chronic eczema/psoriasis-overlap with steroid-responsive recurrence
- dry-eye/meibomian involvement compatible with skin/barrier disease
- IgE historically elevated, consistent with allergic/Th2 tone
- prior calprotectin elevation has normalized to 13.3 ug/g
- stool occult blood and stool RBCs now exist despite normal calprotectin
- platelets/WBC remain active enough to need their own workup pathway
- vegetarian/fiber/probiotic periods coincided with eczema improvement
- alcohol worsens stool looseness and plausibly worsens gut barrier/sleep/BP noise

The important split: **skin/allergy may still be active while gut mucosal inflammation is quiet.** Do not collapse those into one “gut inflammation” story.

## Action implications

| Action | Why it is reasonable | Boundary |
|---|---|---|
| Continue plant-forward/fiber tuning if tolerated | Supports stool quality, SCFA biology, and general gut health | Not proven to prevent diverticular bleeding |
| Keep probiotic/CBM588 experiments symptom-focused | Microbiome support may help gut/skin symptoms | Not a substitute for occult-blood workup |
| Maintain alcohol abstinence during the experiment | Reduces gut irritation, sleep/BP noise, and relapse confounding | Not proven as a direct eczema-diverticular therapy |
| Treat eczema as its own disease | Persistent steroid cycling suggests dermatology value | Do not infer hidden GI flare from skin rebound |
| Track IgE/CRP/ESR only as context | May help partition allergic/systemic inflammation | Does not localize bleeding |
| Escalate stool blood through GI branch | Positive FOB/RBC is a bleeding-source question | SIBO/eczema do not explain it |

Tests such as tryptase, zonulin, or fecal SCFA are not core next steps unless a clinician or specific symptom pattern would act on them. Dermatology review has higher practical yield than adding speculative gut-barrier markers.

## Evidence / context

**Microbiome actionability anchors**

- Broad stool microbiome testing is not ready as a general decision tool. A 2025 international consensus states that clinical usefulness remains scarce/limited and warns that direct-to-consumer testing can waste resources and drive inappropriate interventions. PMID: 39647502.
- Fiber/whole-food pattern remains the highest-yield microbiome lever. A 2025 human review supports modest anti-inflammatory effects for high-fiber diets, with inulin and resistant starch showing clearer short-term signals, but not enough precision to prescribe a single fiber type by test result. PMID: 40076626.
- TMAO is an associated CVD biomarker in meta-analysis, but it is not a practical substitute for Lp(a), ApoB/LDL, BP, smoking, or plaque/valve imaging decisions. PMID: 29020409.
- Histamine intolerance lacks a validated biomarker and should be handled only as a reproducible food-response pattern, not as a default unifying gut-skin diagnosis. PMID: 41009760.

**Established / stronger anchors**

- AD and IBD association is supported by large meta-analyses; effect sizes are real but not automatically large enough for personal prediction. PMID: 39678631, PMID: 39602916.
- Mendelian randomization supports a possible causal AD -> IBD relationship, but this is not evidence for AD -> diverticular bleeding. PMID: 34964870.
- AD associates with broader autoimmune comorbidity, especially with more severe disease. PMID: 35469843.

**Plausible but not decisive**

- Gut-skin reviews support microbiome, barrier, SCFA, oxidative-stress, and immune-crosstalk mechanisms. These mechanisms fit symptom co-movement without establishing structural diverticular outcomes. PMID: 41269405, PMID: 38623584, PMID: 41897446.
- JAK/STAT and overlapping cytokine pathways matter in both skin and intestinal immune disease, but shared drug classes are not proof of one shared diagnosis.

**Weak / speculative for this KB**

- The psoriasis-diverticulitis signal is small and observational (reported HR/relative risk around 1.16 in one cohort). It is not a bleeding-risk rule and should not dominate management. PMID: 31039227.
- A 2026 Taiwan AD/IBD case-control signal is hypothesis-generating and does not justify changing diverticular strategy by itself. PMID: 41858144.

## Bottom line

Use eczema as a clue about systemic/allergic tone and as a reason to keep microbiome/diet experiments evidence-tiered. Do not let it become a unifying explanation for everything. Positive stool blood goes to the bleeding workup; persistent thrombocytosis goes to the platelet pathway; bloating goes to SIBO/SUDD symptom tracking; eczema gets its own dermatology/skin-barrier management.